ALCAM是声门型喉鳞状细胞癌肿瘤侵袭性和预后不良的生物标志物
本研究旨在验证ALCAM在声门型喉鳞状细胞癌中的预后价值,采用免疫组化检测263例接受手术加颈淋巴结清扫的声门型喉鳞癌标本中ALCAM蛋白水平。结果显示ALCAM在48.7%的样本中表达、在36.5%的样本中过表达,过表达与淋巴结转移(p=0.030)、淋巴血管侵犯(p=0.0002)、高级别肿瘤(p=0.025)和肿瘤复发(p=0.043)相关。多因素生存分析显示ALCAM过表达与淋巴结转移作为预后变量存在过拟合。
要点
- ALCAM在48.7%的声门型喉鳞癌中表达,36.5%过表达。
- ALCAM过表达与淋巴结转移(p=0.030)、淋巴血管侵犯(p=0.0002)相关。
- ALCAM过表达还与高级别肿瘤(p=0.025)、肿瘤复发(p=0.043)相关。
核心结论
- ALCAM高表达与声门型喉鳞状细胞癌的侵袭性表型相关。
研究设计与样本
- 对263例接受手术加颈淋巴结清扫的声门型喉鳞状细胞癌标本进行免疫组化检测ALCAM蛋白水平,以验证其预后价值。
主要发现
- ALCAM在48.7%的声门型喉鳞癌样本中表达,在36.5%的样本中过表达。
- ALCAM过表达与淋巴结转移相关(p=0.030)。
- ALCAM过表达与淋巴血管侵犯相关(p=0.0002)。
- ALCAM过表达与高级别肿瘤相关(p=0.025)。
- ALCAM过表达与肿瘤复发相关(p=0.043)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is the second most frequent head and neck tumor. Prognosis of patients with LSCC has not improved in recent decades, showing a need for the identification of prognostic biomarkers and new therapeutic targets. Recently, we showed that ALCAM overexpression was associated with glottic LSCC prognosis. OBJECTIVES AND METHODS: Aiming to validate the prognostic value of ALCAM, we evaluate the ALCAM protein levels by immunohistochemistry in 263 glottic LSCC surgically treated with neck dissection. RESULTS: ALCAM was expressed in 48.7% and overexpressed in 36.5% of glottic LSCC samples. ALCAM overexpression was associated with lymph node metastasis (p = 0.030), lymphovascular involvement (p = 0.0002), high-grade tumors (p = 0.025), and tumor relapse (p = 0.043). Multivariate survival analyses showed an overfitting between ALCAM overexpression and lymph node metastasis as a prognostic variable. CONCLUSIONS: High ALCAM expression was associated with an aggressive glottic LSCC profile.
引用
- Nicolau-Neto P, Peryassú BC, de Carvalho FN, et al. ALCAM is a biomarker of tumor aggressiveness and worse prognosis in glottic laryngeal squamous cell carcinoma. Head Neck. 2024. PMID: 38196304. doi:10.1002/hed.27635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。